NCT06350006View on ClinicalTrials.gov

SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

PHASE1RecruitingINTERVENTIONAL
Enrollment

924

Participants

Timeline

Start Date

May 29, 2024

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2028

Conditions
Cldn18.2-positive Advanced Solid Tumor
Interventions
DRUG

SHR-A1904; Adebrelimab

SHR-A1904 combined with Adebrelimab: SHR-A1904+ Adebrelimab

DRUG

SHR-A1904; CAPOX; Adebrelimab

SHR-A1904 combined with Adebrelimab and CAPOX (Capecitabine, Oxaliplatin)

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY